Rockeby gains European patent for VVC test
Australia-listed, Singapore-based health care group Rockeby biomed has been granted a European patent for its CanDia5 candida assay.
CanDia5 is a blood-based point-of-care test kit to detect vulvo-vaginal candidiasis during pregnancy, which has been associated with intrauterine growth retardation. The firm says recent evidence has also shown that screening and treatment of VVC during pregnancy significantly reduces the prevalence of preterm labour.
The patent (European patent no 1 381 864) relates to a method and a means of diagnosing Candida infection. This extends Rockeby's patent coverage of its technology to the UK, as well as Australia, Japan and the USA, where the test is already patented. The firm currently markets and distributes CanDia5 in Australia, New Zealand, Italy, Singapore and the United Arab Emirates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze